Panobinostat Lactate Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg, 15 mg, 20 mg
Reference Brands: Farydak (USA/EU),
Category:
Oncology Cancer Care
Panobinostat Lactate is available in Capsules
and strengths such as 10 mg, 15 mg, 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Panobinostat Lactate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Panobinostat Lactate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Panobinostat is a targeted anticancer medication that belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. It is used in the treatment of certain cancers and has shown particular effectiveness in patients with multiple myeloma who have received prior therapies. Panobinostat works by inhibiting HDAC enzymes, which play an important role in regulating gene expression within cells. By blocking these enzymes, the drug causes hyperacetylation of histones and other intracellular proteins, allowing the activation of genes that can suppress tumor growth.
Through this mechanism, Panobinostat helps inhibit the proliferation of cancer cells and promotes programmed cell death, also known as apoptosis. In addition to affecting gene expression, the drug can also trigger cellular death receptor pathways, further contributing to the destruction of malignant cells. Preclinical and clinical studies have demonstrated that Panobinostat is a highly potent HDAC inhibitor, showing strong anticancer activity even at very low concentrations.
Panobinostat has been evaluated in both oral and intravenous formulations across various tumor types and continues to be studied for its potential role in treating solid tumors and other hematologic malignancies. It is marketed under the brand name Farydak and represents an important advancement in targeted cancer therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing